Scientifically Rigorous Safety Assessments That Drive Approval Confidence
At Indivirtus Healthcare Services Pvt. Ltd., our advanced In Vivo Genotoxicity Testing services provide comprehensive evaluation of genetic damage potential using industry-leading OECD-compliant methodologies. From our state-of-the-art Micronucleus Testing and innovative Comet Assay to sophisticated Transgenic Rodent Mutation Assays, we deliver scientifically defensible, regulator-ready data that accelerates your path to IND, NDA, and global regulatory approvals.
Our comprehensive testing portfolio includes cutting-edge OECD-compliant Micronucleus Testing (OECD 474), advanced Comet Assay (OECD 489), and sophisticated Transgenic Rodent Mutation Assays, delivering unparalleled scientific accuracy for confident regulatory decision-making.
In vivo genotoxicity testing provides irreplaceable insights into real-world genetic safety, accounting for complex biological processes including metabolism, distribution, and DNA repair mechanisms that in vitro tests cannot capture, making it indispensable for regulatory compliance and patient safety.
As your dedicated CRO partner, Indivirtus Healthcare Services combines deep scientific expertise with proven regulatory knowledge to deliver genotoxicity solutions that not only meet current standards but anticipate future regulatory expectations, ensuring your global submission success.
At Indivirtus Healthcare Services, our In Vivo Genotoxicity Testing is led by board-certified toxicologists and experienced scientists with decades of combined regulatory expertise. We employ state-of-the-art GLP-compliant facilities and cutting-edge methodologies to conduct Micronucleus Testing, Comet Assays, and Transgenic Rodent Mutation Assays with exceptional precision and reliability.
Our systematic approach ensures submission-ready study reports that meet the exacting standards of OECD 474, 489, 488, ICH S2(R1), and FDA Genotoxicity Guidance. Every study is designed with your specific regulatory pathway in mind, providing the scientific foundation for confident regulatory submissions worldwide.
Comprehensive GLP-Compliant Study Protocol: Detailed, scientifically rigorous testing plan tailored to your compound and regulatory requirements.
Complete Raw Data & Statistical Analysis: Thorough data package with robust statistical evaluation and quality assurance documentation.
Professional OECD-Compliant Study Report: Submission-ready comprehensive report meeting international regulatory standards and expectations.
Expert Scientific Interpretation: Clear regulatory conclusions with scientific rationale and strategic guidance for your submission pathway.
Our In Vivo Genotoxicity Testing services exceed the most stringent international regulatory requirements, ensuring your data meets or surpasses global regulatory expectations. By maintaining compliance with the latest industry standards and anticipating regulatory evolution, we provide testing solutions that build regulatory confidence and accelerate approval timelines.
Our In Vivo Genotoxicity Testing services are specifically designed for pharmaceutical and biotech companies navigating complex regulatory landscapes. Whether you're developing novel therapeutic compounds, conducting safety assessments for clinical trial applications, or addressing regulatory queries about impurities, our comprehensive testing solutions provide the scientific foundation for confident regulatory submissions. Key applications include evaluating genetic safety for new drug candidates, supporting Phase I clinical trial applications, meeting regulatory requirements for drug impurities, and providing follow-up testing for positive in vitro results.
Indivirtus Healthcare Services stands as the preferred partner for pharmaceutical companies worldwide, delivering scientifically superior genotoxicity testing backed by internationally recognized toxicology experts and cutting-edge laboratory capabilities. Our commitment to scientific excellence, regulatory intelligence, and client success ensures reliable, defensible results delivered on time and with complete confidentiality.
With our proven track record of regulatory success and unwavering commitment to quality, we empower your organization with the robust genotoxicity data needed to advance your drug development programs, accelerate regulatory approvals, and ultimately bring safer therapies to patients worldwide.
In vivo genotoxicity testing evaluates genetic damage potential by administering test compounds to living animals, providing comprehensive assessment of chromosomal and DNA damage that accounts for complex biological processes like metabolism, distribution, and DNA repair mechanisms that in vitro tests cannot capture.
The Micronucleus Test (OECD 474) is the gold-standard method for detecting structural or numerical chromosomal damage by measuring micronuclei formation in dividing cells, typically bone marrow or peripheral blood cells in rodents. It's essential for regulatory submissions and follow-up testing of positive in vitro results.
The Comet Assay (OECD 489) is ideal for evaluating DNA strand breaks in specific target tissues like liver, stomach, or other organs after systemic exposure. It's particularly valuable for compounds with short half-lives, reactive intermediates, or when tissue-specific genotoxicity assessment is required.
Transgenic Rodent Mutation Assays use genetically engineered rodents carrying reporter genes to directly detect gene mutations after compound exposure. They provide unique mechanistic insights into mutagenic pathways and offer superior sensitivity for detecting mutagenic effects across multiple tissues.
Yes, all our in vivo genotoxicity studies are conducted under strict GLP compliance in accordance with OECD guidelines, ensuring data quality, reproducibility, and regulatory acceptance worldwide. Our facilities maintain current GLP certifications and undergo regular regulatory inspections.
Our complete service package includes OECD-compliant Micronucleus Testing, advanced Comet Assay, and Transgenic Rodent Mutation Assays, delivered with comprehensive GLP protocols, detailed study reports, statistical analysis, and expert regulatory interpretation.
Pharmaceutical and biotech companies developing new drug candidates, conducting IND/NDA submissions, assessing drug impurities for regulatory compliance, or requiring follow-up testing for positive in vitro results benefit most from our specialized genotoxicity testing solutions.
Our services strictly adhere to international standards including OECD 474, 489, 488, ICH S2(R1), and FDA Genotoxicity Guidance, ensuring worldwide regulatory acceptance. We stay current with evolving guidelines and maintain compliance with regional requirements across major pharmaceutical markets.
Each study includes comprehensive GLP-compliant protocols, complete raw data with robust statistical analysis, OECD-compliant final reports, and expert scientific interpretation with regulatory conclusions, all designed to support successful regulatory submissions.
Absolutely. Our services are fully customizable based on your specific compounds, regulatory requirements, submission timelines, and strategic objectives. We work closely with clients to design optimal study protocols that address their unique regulatory pathway needs.
We provide scientifically rigorous, OECD-compliant data with clear regulatory interpretation and strategic guidance, helping clients navigate complex regulatory requirements efficiently. Our expertise in global regulatory standards ensures data packages that build regulator confidence and accelerate approval timelines.